Full Text:   <1143>

Summary:  <1226>

CLC number: R446

On-line Access: 2019-06-06

Received: 2019-01-29

Revision Accepted: 2019-04-14

Crosschecked: 2019-05-23

Cited: 0

Clicked: 2114

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2019 Vol.20 No.7 P.605-612

http://doi.org/10.1631/jzus.B1900051


Exosome-derived galectin-9 may be a novel predictor of rejection and prognosis after liver transplantation


Author(s):  Ai-Bin Zhang, Yi-Fan Peng, Jun-Jun Jia, Yu Nie, Shi-Yu Zhang, Hai-Yang Xie, Lin Zhou, Shu-Sen Zheng

Affiliation(s):  Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China; more

Corresponding email(s):   shusenzheng@zju.edu.cn

Key Words:  Liver transplantation, Acute cellular rejection, Exosome, Galectin-9


Ai-Bin Zhang, Yi-Fan Peng, Jun-Jun Jia, Yu Nie, Shi-Yu Zhang, Hai-Yang Xie, Lin Zhou, Shu-Sen Zheng. Exosome-derived galectin-9 may be a novel predictor of rejection and prognosis after liver transplantation[J]. Journal of Zhejiang University Science B, 2019, 20(7): 605-612.

@article{title="Exosome-derived galectin-9 may be a novel predictor of rejection and prognosis after liver transplantation",
author="Ai-Bin Zhang, Yi-Fan Peng, Jun-Jun Jia, Yu Nie, Shi-Yu Zhang, Hai-Yang Xie, Lin Zhou, Shu-Sen Zheng",
journal="Journal of Zhejiang University Science B",
volume="20",
number="7",
pages="605-612",
year="2019",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1900051"
}

%0 Journal Article
%T Exosome-derived galectin-9 may be a novel predictor of rejection and prognosis after liver transplantation
%A Ai-Bin Zhang
%A Yi-Fan Peng
%A Jun-Jun Jia
%A Yu Nie
%A Shi-Yu Zhang
%A Hai-Yang Xie
%A Lin Zhou
%A Shu-Sen Zheng
%J Journal of Zhejiang University SCIENCE B
%V 20
%N 7
%P 605-612
%@ 1673-1581
%D 2019
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1900051

TY - JOUR
T1 - Exosome-derived galectin-9 may be a novel predictor of rejection and prognosis after liver transplantation
A1 - Ai-Bin Zhang
A1 - Yi-Fan Peng
A1 - Jun-Jun Jia
A1 - Yu Nie
A1 - Shi-Yu Zhang
A1 - Hai-Yang Xie
A1 - Lin Zhou
A1 - Shu-Sen Zheng
J0 - Journal of Zhejiang University Science B
VL - 20
IS - 7
SP - 605
EP - 612
%@ 1673-1581
Y1 - 2019
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1900051


Abstract: 
acute cellular rejection (ACR) remains a major concern after liver transplantation. Predicting and monitoring acute rejection by non-invasive methods are very important for guiding the use of immunosuppressive drugs. Many studies have shown that exosomes and their contents are potential biomarkers for various liver diseases. Here, we identify and validate the role of exosomes and galectin-9 in ACR after liver transplantation. exosomes were isolated from three sets of paired patients, with and without ACR, and the proteins within the exosomes were isolated and identified. Candidate proteins were then validated using a tissue microarray containing resected liver samples from 73 ACR and 63 non-rejection patients. Finally, protein expression and clinical manifestations were included in Kaplan-Meier survival and Cox regression analyses. Circulating exosomes were isolated from ACR and non-rejection patients and characterized using transmission electron microscopy and western blotting for CD63/CD81. Western blotting experiments revealed higher levels of galectin-9 protein in circulating exosomes from ACR recipients. Immunohistochemical analysis of the tissue microarray showed that the expression of galectin-9 in resected liver was significantly higher in the ACR group than in the non-rejection group (P<0.05). Higher levels of galectin-9 expression in resected livers were associated with poorer prognosis (P<0.05). exosome-derived galectin-9 may be a novel predictor of rejection and prognosis after liver transplantation.

外泌体来源的半乳糖凝集素-9预测肝移植术后排斥发生及预后

目的:外泌体及其内容物是各种肝脏疾病的潜在生物标志物.本研究探索外泌体及其内容物在肝移植排斥反应及预后中的作用.
创新点:本研究发现外泌体及内含物半乳糖凝集素-9(galectin-9)在肝移植术后排斥及预后预测中发挥重要作用.
方法:分别从急性排斥和肝功能稳定患者提取外泌体,进行分离、鉴定并检测其内含蛋白.候选蛋白通过在73个急性排斥病人和63个肝功能稳定病人切除肝的组织芯片中进行验证.最后将蛋白表达量和临床参数纳入Kaplan-Meier生存率和Cox回归分析.
结论:外泌体来源的galectin-9可作为预测肝移植术后排斥发生及预后的生物学指标.

关键词:肝移植;急性排斥反应;外泌体;半乳糖凝集素-9(Galectin-9)

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Ashokkumar C, Soltys K, Mazariegos G, et al., 2017. Predicting cellular rejection with a cell-based assay: preclinical evaluation in children. Transplantation, 101(1):131-140.

[2]Boix F, Millan O, san Segundo D, et al., 2016. High expression of CD38, CD69, CD95 and CD154 biomarkers in cultured peripheral T lymphocytes correlates with an increased risk of acute rejection in liver allograft recipients. Immunobiology, 221(5):595-603.

[3]Chagan-Yasutan H, Shiratori B, Siddiqi UR, et al., 2010. The increase of plasma galectin-9 in a patient with insulin allergy: a case report. Clin Mol Allergy, 8:12.

[4]Chen DJ, Peng WH, Jiang H, et al., 2017. Noninvasive detection of acute renal allograft rejection by measurement of soluble Tim-3 in urine. Mol Med Rep, 16(1):915-921.

[5]Dardalhon V, Anderson AC, Karman J, et al., 2010. Tim-3/ galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J Immunol, 185(3):1383-1392.

[6]Demetris AJ, Bellamy C, Hübscher SG, et al., 2016. 2016 comprehensive update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody-mediated rejection. Am J Transplant, 16(10):2816-2835.

[7]Dieudé M, Bell C, Turgeon J, et al., 2015. The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. Sci Transl Med, 7(318):318ra200.

[8]Gupta S, Thornley TB, Gao WD, et al., 2012. Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs. J Clin Invest, 122(7):2395-2404.

[9]Huang HT, Lu YF, Zhou T, et al., 2018. Innate immune cells in immune tolerance after liver transplantation. Front Immunol, 9:2401.

[10]Kerr N, García-Contreras M, Abbassi S, et al., 2018. Inflammasome proteins in serum and serum-derived extracellular vesicles as biomarkers of stroke. Front Mol Neurosci, 11:309.

[11]Kim N, Yoon YI, Yoo HJ, et al., 2016. Combined detection of serum IL-10, IL-17, and CXCL10 predicts acute rejection following adult liver transplantation. Mol Cells, 39(8):639-644.

[12]https://doi.org/10.14348/molcells.2016.0130

[13]Kurose Y, Wada J, Kanzaki M, et al., 2013. Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease. BMC Nephrol, 14:23.

[14]Lazar E, Benedek T, Korodi S, et al., 2018. Stem cell-derived exosomes—an emerging tool for myocardial regeneration. World J Stem Cells, 10(8):106-115.

[15]Lee EC, Kim SH, Park SJ, 2017. Outcomes after liver transplantation in accordance with ABO compatibility: a systematic review and meta-analysis. World J Gastroenterol, 23(35):6516-6533.

[16]Li YM, Shi YY, Li Y, et al., 2018. Soluble Tim-3 and Gal-9 are associated with renal allograft dysfunction in kidney transplant recipients: a cross-sectional study. Int Immunopharmacol, 55:330-335.

[17]Lim JH, Lee CH, Kim KY, et al., 2018. Novel urinary exosomal biomarkers of acute T cell-mediated rejection in kidney transplant recipients: a cross-sectional study. PLoS ONE, 13(9):e0204204.

[18]Meszaros M, Ursic-Bedoya J, Faure S, et al., 2019. Immuno-suppression minimization trials in liver transplantation: can we predict humoral response to assess eligibility? Hepatology, 69(5):2302-2303.

[19]Mousavi S, Moallem R, Hassanian SM, et al., 2019. Tumor-derived exosomes: potential biomarkers and therapeutic target in the treatment of colorectal cancer. J Cell Physiol, 234(8):12422-12432.

[20]Naderi-Meshkin H, Lai X, Amirkhah R, et al., 2019. Exosomal lncRNAs and cancer: connecting the missing links. Bioinformatics, 35(2):352-360.

[21]Naka EL, Ponciano VC, Cenedeze MA, et al., 2009. Detection of the Tim-3 ligand, galectin-9, inside the allograft during a rejection episode. Int Immunopharmacol, 9(6):658-662.

[22]Pike R, Thomas N, Workman S, et al., 2016. PD1-expressing T cell subsets modify the rejection risk in renal transplant patients. Front Immunol, 7:126.

[23]Qiao XW, Jiang K, Nie J, et al., 2014. Increased expression of Tim-3 and its ligand galectin-9 in rat allografts during acute rejection episodes. Biochem Biophys Res Commun, 445(3):542-548.

[24]Raschzok N, Reutzel-Selke A, Schmuck RB, et al., 2015. CD44 and CXCL9 serum protein levels predict the risk of clinically significant allograft rejection after liver transplantation. Liver Transpl, 21(9):1195-1207.

[25]Saitoh H, Ashino Y, Chagan-Yasutan H, et al., 2012. Rapid decrease of plasma galectin-9 levels in patients with acute HIV infection after therapy. Tohoku J Exp Med, 228(2):157-161.

[26]Sakuishi K, Jayaraman P, Behar SM, et al., 2011. Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends Immunol, 32(8):345-349.

[27]Schlegel A, Linecker M, Kron P, et al., 2017. Risk assessment in high- and low-meld liver transplantation. Am J Transplant, 17(4):1050-1063.

[28]Shen T, Lin BY, Jia JJ, et al., 2014. A modified protocol with rituximab and intravenous immunoglobulin in emergent ABO-incompatible liver transplantation for acute liver failure. Hepatobiliary Pancreat Dis Int, 13(4):395-401.

[29]Sood S, Haifer C, Yu LJ, et al., 2017. A novel immune function biomarker identifies patients at risk of clinical events early following liver transplantation. Liver Transpl, 23(4):487-497.

[30]Su EW, Bi SG, Kane LP, 2011. Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology, 21(10):1258-1265.

[31]Tang ZH, Liang SW, Potter J, et al., 2013. Tim-3/galectin-9 regulate the homeostasis of hepatic NKT cells in a murine model of nonalcoholic fatty liver disease. J Immunol, 190(4):1788-1796.

[32]Vallabhajosyula P, Korutla L, Habertheuer A, et al., 2017. Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue. J Clin Invest, 127(4):1375-1391.

[33]van den Hoogen LL, van Roon JAG, Mertens JS, et al., 2018. Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis, 77(12):1810-1814.

[34]Vitalone MJ, Wei L, Fujiki M, et al., 2016. Liver microRNA profile of induced allograft tolerance. Transplantation, 100(4):781-790.

[35]Wang Y, Zhang M, Liu ZW, et al., 2014. The ratio of circulating regulatory T cells (Tregs)/Th17 cells is associated with acute allograft rejection in liver transplantation. PLoS ONE, 9(11):e112135.

[36]Zhou YX, Yang XJ, Zhang H, et al., 2015. The roles of T helper type 17/regulatory T cells in acute rejection after liver transplantation in rats. Transplantation, 99(6):1126-1131.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE